Navigation Links
GeneLink Announces New Licensing Partner
Date:1/13/2011

ORLANDO, Fla., Jan. 13, 2011 /PRNewswire/ -- GeneLink, Inc. (OTC Bulletin Board: GNLK), a leading consumer genomics biotech company, has announced that Robert B. Trussell, former CEO and founder of Tempur-Pedic, Inc., has recently formed a company to distribute genetically customized products developed by GeneLink. Mr. Trussell, through his new company, intends to market the product line utilizing techniques similar to those he used so successfully at Tempur-Pedic, including internet sales, short form TV and infomercials, newspapers, magazines, trade publications and radio.

Mr. Trussell, who has brought back together a number of the former key staff members responsible for the early success of Tempur-Pedic, said, "We're especially excited to be teamed up with a company so similar to Tempur-Pedic, with unique technology with a point of difference that offers extraordinary value to consumers, a high end product line, and first mover status in a hot category."  He added, "Numerous patents and patents pending by GeneLink will allow us to focus exclusively on developing the marketing of this remarkable product line.  We're especially excited to see so many of the original team members coming together again on another venture of this magnitude.  We are all really looking forward to the challenges and opportunities that lie ahead!"

Bernard L. Kasten Jr., M.D. GeneLink's Executive Chairman and CEO added, "We are very excited to be partnering with Bobby Trussell and his team.  Bobby has long been a supporter of both GeneLink and our direct selling subsidiary, GeneWize. Bobby's organization has most recently been instrumental in developing new Affiliate acquisition techniques with and for GeneWize. We anticipate these efforts will be increasingly fruitful as our working relationship expands. This new relationship provides us with a world class partner who has a proven track record in marketing scientifically advanced consumer products like our genetically-guided nutrition and skin care.  Our agreement also provides GeneLink with some of the additional financial capital needed to help us expand R&D, product development, product validation, infrastructure and continued leadership in regulatory compliance and quality.  As the pioneer in genetically-guided nutrition and skin care, GeneLink continues to focus on strengthening our leadership position and leading the growth in consumer genetics.  Along with our two other distribution channels, our relationship with Bobby and his team should help expand both our top and bottom line growth."

About GeneLink Biosciences, Inc.:

GeneLink is a 16-year old leading biosciences company specializing in consumer genomics. GeneLink's patented technologies include proprietary DNA test assessments linked to personalized health, beauty and wellness applications and products. Its DNA assessments provide information that enables the customization of nutritional and skincare products designed and manufactured to fulfill each individual consumer's wellness needs. For more information visit www.genelinkbio.com

About Robert B. Trussell, Jr.:

Robert B. Trussell, Jr., 59, has served as a member of Tempur-Pedic International's Board of Directors or its predecessors since 1992, and has served as Vice Chairman of the Board of Directors since April 2006. Mr. Trussell served as Chief Executive Officer of Tempur-Pedic International or its predecessors from 1992 until May 2006. Tempur-Pedic International Inc. (NYSE: TPX) manufactures and distributes mattresses and pillows made from its proprietary TEMPUR® pressure-relieving material and is the worldwide leader in premium and specialty sleep.

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE GeneLink, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GeneLink Reports Third Quarter Results
2. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
3. GeneLink Announces HelixLife Private Label Distribution Agreement
4. GeneLink Reports First Quarter Gains
5. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
6. Caliper Life Sciences Announces Preliminary Results for the Fourth Quarter and 2010
7. Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million
8. Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
9. WaferGen Announces General Availability of Quick-Turnaround SmartChip Custom Panels
10. PAREXEL Announces Date of Second Quarter Fiscal Year 2011 Earnings Release and Conference Call
11. New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... Clinovo ... free and validated Electronic Data Capture (EDC) system ClinCaptureand its new Contract Research ... West Coast 2016 Conference in San Mateo, California on February 10th and 11th. ...
(Date:2/9/2016)... ... 2016 , ... The American Academy of Thermology (AAT) has announced ... AAT Member Certification Qualification Course for Technicians via a two part webinar on July ... a detailed review of hardware, software, and camera setup/operations, aligns with the in-person member ...
(Date:2/9/2016)... ... February 09, 2016 , ... PharmApprove ... for the National Organization for Rare Disorders (NORD). Dorman will lead PharmApprove efforts ... are heard throughout the drug regulatory review process. , “Adding Diane Dorman is ...
(Date:2/9/2016)... YORK , Feb. 9, 2016 This ... analyzes the current and future prospects of the market ... this report include companies engaged in the manufacture of ... an executive summary with a market snapshot providing the ... scope of this report. This section also provides the ...
Breaking Biology Technology:
(Date:1/28/2016)... Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), a ... its second quarter ended December 31, 2015. ... of fiscal 2016 increased 2 percent compared to the comparable quarter ... of fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... income for the first quarter of fiscal 2016 grew 9 percent ...
(Date:1/25/2016)...  Glencoe Software, the world-leading supplier of image data ... provide the data management solution OMERO Plus for the ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of ... states such as health and disease, the presence or ...
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
Breaking Biology News(10 mins):